MannKind Corporation to Participate in 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) will have its CEO, Michael Castagna, PharmD, participating in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 4:15 PM ET. This event will be accessible via a webcast from the Company’s website, with a replay available for 14 days post-event. MannKind specializes in inhaled therapeutic products for patients with endocrine and orphan lung diseases, notably commercializing Afrezza®, an FDA-approved ultra-rapid-acting inhaled insulin available by prescription in the U.S. and Brazil.

WESTLAKE VILLAGE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 at 4:15 pm (ET). Interested parties can access a link to the webcast from the Events & Presentations section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil where it is commercialized by the Company’s partner Biomm SA.  MannKind is headquartered in Westlake Village, California, with a manufacturing and R&D facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. Please visit www.mannkindcorp.com to learn more.

Contact:
818-661-5000
ir@mannkindcorp.com 

FAQ

What is MannKind Corporation's participation in the 2021 RBC Capital Markets Global Healthcare Conference?

MannKind Corporation will have its CEO, Michael Castagna, participate in a Fireside Chat on May 18, 2021, at 4:15 PM ET.

Where can I access the webcast for MannKind's presentation at the RBC Conference?

The webcast can be accessed from the Events & Presentations section of MannKind's website.

What is Afrezza and how is it related to MannKind Corporation?

Afrezza is MannKind's inhaled insulin product, which is FDA-approved and the only ultra-rapid-acting mealtime insulin available by prescription in the U.S.

How long will the replay of MannKind's Fireside Chat be available?

The replay of the Fireside Chat will be available for 14 days following the live presentation.

What types of diseases does MannKind Corporation focus on?

MannKind Corporation focuses on inhaled therapeutic products for patients with endocrine and orphan lung diseases.